Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly
NCT00225979
·
clinicaltrials.gov ↗
PHASE3
Phase
COMPLETED
Status
100
Enrollment
INDUSTRY
Sponsor class
Conditions
Acromegaly
Interventions
DRUG:
Octreotide LAR
Sponsor
Novartis Pharmaceuticals